Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

D3 Bio Raises $62 Million in Series A+ Round for Next-Gen KRAS G12C Inhibitor

publication date: Apr 8, 2024

D3 Bio, a Shanghai oncology biotech, closed a $62 million Series A+ financing round, a large amount for an early-stage company in the past few years. The funding will use the funds to ramp up development of D3 Bio's preclinical assets and a global clinical trial of D3S-001, a next-gen small molecule KRAS G12C inhibitor that the company believes has best-in-class potential. The A+ round was led by Medicxi, a European life sciences investment firm. In 2020, D3 Bio raised an impressive $200 million in a Series A round. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital